Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 3 Head and Neck Neoplasms 3 Esophageal Neoplasms 3 Prostatic Neoplasms 2 Phyllodes Tumor 2 Neoplasms 2 Carcinoma, Squamous Cell 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Sarcoma 1 Postoperative Complications 1 Oropharyngeal Neoplasms 1 Neoplastic Cells, Circulating 1 Mouth Neoplasms 1 Lymphatic Metastasis 1 High-Risk Cancer 1 Carcinoma, Lobular 1

Interventions

Cisplatin 101 Radiotherapy 53 Brachytherapy 41 Paclitaxel 37 Carboplatin 36 Surveys and Questionnaires 28 Blood Specimen Collection 20 pembrolizumab 19 Radiation 17 Magnetic Resonance Spectroscopy 17 Drug Therapy 17 Colposcopy 16 Methods 14 Bevacizumab 14 Early Intervention, Educational 12 toripalimab 11 Topotecan 11 Radiotherapy, Intensity-Modulated 11 Papanicolaou Test 11 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 11 Chemoradiotherapy 11 Biopsy 11 camrelizumab 10 Mass Screening 10 Gemcitabine 10 Patient Navigation 9 Papillomavirus Vaccines 9 Nivolumab 9 Fluorodeoxyglucose F18 9 Educational Status 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Uterine Cervical Neoplasms × Radiotherapy, Adjuvant × Clear all

NCT04989647 2023-09-07

CERVANTES

The Central and Eastern European Gynecologic Oncology Group

Phase 3 Recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡